Literature DB >> 26416671

Cortical inhibitory deficits in premanifest and early Huntington's disease.

April L Philpott1, Tarrant D R Cummins1, Neil W Bailey2, Andrew Churchyard3, Paul B Fitzgerald2, Nellie Georgiou-Karistianis4.   

Abstract

Although progress has been made towards understanding the gross cortical and subcortical pathology of Huntington's disease (HD), there remains little understanding of the progressive pathophysiological changes that occur in the brain circuits underlying the disease. Transcranial magnetic stimulation (TMS) enables investigation of the functional integrity of cortico-subcortical pathways, yet it has not been widely applied in HD research to date. This study sought to characterise profiles of cortical excitability, including inhibition and facilitation, in groups of premanifest and symptomatic HD participants via the use of TMS. We also investigated the clinical, neurocognitive and psychiatric correlates of cortical excitability to better understand the development of phenotypic heterogeneity. The sample comprised 16 premanifest HD, 12 early symptomatic HD and 17 healthy control participants. Single- and paired-pulse TMS protocols were administered to the left primary motor cortex, with surface electromyography recorded from the abductor pollicis brevis muscle. Short-interval cortical inhibition was significantly reduced in symptomatic HD, compared with premanifest HD and controls, and was significantly correlated with pathological burden and neurocognitive performance. There was also reduced long-interval cortical inhibition in both premanifest and symptomatic HD, compared with controls, which was associated with pathological burden and psychiatric disturbances. Motor thresholds, cortical silent periods and intracortical facilitation did not differ across groups. Our results provide important new insights into pathophysiological changes in cortico-subcortical circuits across disease stages in HD. We propose that neurophysiological measures obtained via TMS have potential utility as endophenotypic biomarkers in HD, given their association with both pathological burden and clinical phenotype.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cortical inhibition; Corticostriatal; GABA; Pathophysiological mechanism; Premanifest Huntington’s disease; Transcranial magnetic stimulation

Mesh:

Substances:

Year:  2015        PMID: 26416671     DOI: 10.1016/j.bbr.2015.09.030

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  11 in total

Review 1.  Developmental origins of cortical hyperexcitability in Huntington's disease: Review and new observations.

Authors:  Carlos Cepeda; Katerina D Oikonomou; Damian Cummings; Joshua Barry; Vannah-Wila Yazon; Dickson T Chen; Janelle Asai; Christopher K Williams; Harry V Vinters
Journal:  J Neurosci Res       Date:  2019-07-28       Impact factor: 4.164

2.  EGF Treatment Improves Motor Behavior and Cortical GABAergic Function in the R6/2 Mouse Model of Huntington's Disease.

Authors:  Felecia M Marottoli; Mercedes Priego; Eden Flores-Barrera; Rohan Pisharody; Steve Zaldua; Kelly D Fan; Giri K Ekkurthi; Scott T Brady; Gerardo A Morfini; Kuei Y Tseng; Leon M Tai
Journal:  Mol Neurobiol       Date:  2019-05-19       Impact factor: 5.590

Review 3.  Alteration of GABAergic neurotransmission in Huntington's disease.

Authors:  Maurice Garret; Zhuowei Du; Marine Chazalon; Yoon H Cho; Jérôme Baufreton
Journal:  CNS Neurosci Ther       Date:  2018-02-21       Impact factor: 5.243

4.  Postnatal and adult consequences of loss of huntingtin during development: Implications for Huntington's disease.

Authors:  Eduardo E Arteaga-Bracho; Maria Gulinello; Michael L Winchester; Nandini Pichamoorthy; Jenna R Petronglo; Alicia D Zambrano; Julio Inocencio; Chirstopher D De Jesus; Joseph O Louie; Solen Gokhan; Mark F Mehler; Aldrin E Molero
Journal:  Neurobiol Dis       Date:  2016-09-10       Impact factor: 5.996

5.  Cortical Features in Child and Adolescent Carriers of Mutant Huntingtin (mHTT).

Authors:  Erin E Reasoner; Ellen van der Plas; Douglas R Langbehn; Amy L Conrad; Timothy R Koscik; Eric A Epping; Vincent A Magnotta; Peggy C Nopoulos
Journal:  J Huntingtons Dis       Date:  2022

6.  Interhemispheric Cortical Inhibition Is Reduced in Young Adults With Developmental Coordination Disorder.

Authors:  Jason L He; Ian Fuelscher; Peter G Enticott; Wei-Peng Teo; Pamela Barhoun; Christian Hyde
Journal:  Front Neurol       Date:  2018-03-23       Impact factor: 4.003

7.  Cortical circuit alterations precede motor impairments in Huntington's disease mice.

Authors:  Johanna Burgold; Elena Katharina Schulz-Trieglaff; Kerstin Voelkl; Sara Gutiérrez-Ángel; Jakob Maximilian Bader; Fabian Hosp; Matthias Mann; Thomas Arzberger; Rüdiger Klein; Sabine Liebscher; Irina Dudanova
Journal:  Sci Rep       Date:  2019-04-29       Impact factor: 4.379

Review 8.  Insights into GABAAergic system alteration in Huntington's disease.

Authors:  Yi-Ting Hsu; Ya-Gin Chang; Yijuang Chern
Journal:  Open Biol       Date:  2018-12-05       Impact factor: 6.411

9.  A Systematic Review of Long-Interval Intracortical Inhibition as a Biomarker in Neuropsychiatric Disorders.

Authors:  Parmis Fatih; M Utku Kucuker; Jennifer L Vande Voort; Deniz Doruk Camsari; Faranak Farzan; Paul E Croarkin
Journal:  Front Psychiatry       Date:  2021-06-02       Impact factor: 4.157

Review 10.  Induced Pluripotent Stem Cells in Huntington's Disease Research: Progress and Opportunity.

Authors:  Adelaide Tousley; Kimberly B Kegel-Gleason
Journal:  J Huntingtons Dis       Date:  2016-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.